• (602) 222-2221
  • Request an Appointment
  • Refer A Patient
Retinal Consultants of Arizona
  • Refer a Patient
  • Request an Appointment
  • (602) 222-2221
  • Patients
    • Locations
    • Info on Covid-19
    • RCA Doctors
    • Accepted Insurance Plans
    • Your Visit
    • Patient Portal
    • Online Bill Pay
    • FAQs
    • About RCA
    • Accessibility Office
  • Referring Providers
    • Refer A Patient
    • RCA Doctors
    • Current Studies & Trials
    • About RCA
  • Conditions We Treat
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Flashes
    • Floaters
    • Low Vision (Referral Only)
    • Macular Degeneration
    • Macular Hole
    • Macular Pucker (Epiretinal Membrane)
    • Posterior Vitreous Separation
    • Retinal Artery Occlusions
    • Retinal Detachment
    • Retinal Tear
    • Retinal Vein Occlusions
    • Uveitis
    • All Conditions
  • Research
    • About the Institute
    • Clinical Trials
    • FDA Approval Process
    • Clinical Research Trial Terms
    • Current Studies & Trials
  • Our Doctors
  • Locations
    • Phoenix Metro
      • Gilbert
      • Mesa
      • Peoria
      • Phoenix – Biltmore
      • Phoenix – North
      • Chandler
      • Scottsdale – McCormick
      • Scottsdale – Hayden & Shea
    • Northern Arizona
      • Flagstaff – Switzer Canyon
      • Bullhead City
      • Flagstaff
      • Kingman
      • Lake Havasu City
      • Payson
      • Prescott
    • Southern Arizona
      • Yuma – 24th St
      • Yuma – 28th St.
      • Yuma Foothills
  • Menu Menu

Retinal Research Institute – Phoenix

Retinal Consultants of Arizona has a strong commitment to medical research and the advancement of treatments for retinal diseases. Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies.

We have been participating in clinical trials since 1998 and are proud that the Retinal Research Institute has become one of the nation’s largest retina & vitreous-specific research organizations. In many instances, RCA is the only retina group in Arizona to offer patient participation in multiple studies addressing multiple eye conditions

Mission / Purpose

Retinal Consultants of Arizona’s mission is to provide the most up to date and effective treatments for patients with retinal diseases.

News

Keep up with new research and findings from recent studies and trials.

Anti-PDGF Combination Agent More Effective Than Ranibizumab Monotherapy for Wet AMD

June 13, 2012/ AMD, Anti-PDGF /by retinalconsultants

“The anti-platelet derived growth factor (PDGF) combination agent Fovista (Ophthotech Corp.) showed statistically significant superior efficacy over ranibizumab (Lucentis, Genentech) monotherapy for the treatment of wet AMD, according to the results of a phase 2b study, which were recently reported in an Ophthotech release…” Retinal Consultants of AZ is committed to clinical research and the […]

Read more
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png 0 0 retinalconsultants https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png retinalconsultants2012-06-13 09:00:412012-06-13 09:00:41Anti-PDGF Combination Agent More Effective Than Ranibizumab Monotherapy for Wet AMD
Page 66 of 66«‹646566

Current Studies & Trials

Find out what current studies and trials we are enrolling for.

Learn More

Interested in a Clinical Trial?

If you or someone you know is interested in more information about our clinical research trials, please contact us.

(602) 222-2221

Clinical Trials About RCA

About Us

About RCA >

Blog >

Careers >

Quick Links

Refer a Patient >

Request Appointment >

Contact Us >

Pay My Bill >

Follow Us On Social

© Copyright 2022 Retinal Consultants of Arizona | Privacy Policy | No Surprises Act (HR133) Notice | Accessibility Office | Non-Discrimination Policy
Scroll to top